PRESS RELEASE 2018

• Ferring announces recipients of 2018-19 Innovation Grants

Ferring Pharmaceuticals today announced the recipients of the 2018-19 Ferring Innovation Grants Program, an annual initiative of the Ferring Research Institute (FRI) based in San Diego.

• Ferring announces retirement of Michel Pettigrew, President of the Executive Board and Chief Operating Officer

Ferring Pharmaceuticals today announced that Michel Pettigrew, President of the Executive Board and Chief Operating Officer.

• Ferring Pharmaceuticals and Evotec AG form strategic research alliance in reproductive medicine and women’s health

Ferring Pharmaceuticals and Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced a strategic research alliance.

• Ferring and Celmatix launch ambitious genomics collaboration to advance care in reproductive medicine and women’s health

Ferring Pharmaceuticals and Celmatix today announced an ambitious genomics collaboration aimed at uncovering new insights into ovarian health.

• New analysis of Rekovelle® data further supports use of AMH to personalise fertility treatment

Ferring Pharmaceuticals announced today a new analysis* of data from the Phase 3 ESTHER-1 trial.

• Ferring’s heat-stable carbetocin could save thousands of women’s lives by preventing excessive bleeding after childbirth

Ferring Pharmaceuticals today announced new data demonstrating that its heat-stable formulation of carbetocin could significantly improve maternal health.

• Ferring signs global agreement to commercialise novel gene therapy for bladder cancer patients

Ferring Pharmaceuticals today announced the signing of an agreement giving the company the option to secure global rights for a novel gene therapy.

• Ferring acquires innovative biotechnology company and microbiome pioneer Rebiotix Inc.

Ferring Pharmaceuticals and Rebiotix Inc. today announce that they have agreed to the acquisition of Rebiotix by Ferring.

• Nocturia: the most common cause of a poor night’s sleep, say experts on World Sleep Day

On World Sleep Day, scientists are highlighting the number one reason that people are waking up at night – nocturia.

• Ferring announces positive outcome of European Decentralised Procedure (DCP) for Testavan®, a treatment for men with hypogonadism

Ferring Pharmaceuticals today announced the positive outcome of the European Decentralised Procedure (DCP) for Testavan®.